Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Frequently asked questions
What sector does Catalyst Pharmaceuticals Inc (CPRX) operate in?
Catalyst Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Catalyst Pharmaceuticals Inc (CPRX) current stock price?
As of the latest data, Catalyst Pharmaceuticals Inc stock price is $31.49, with a previous close of $31.49.
What is Catalyst Pharmaceuticals Inc (CPRX) current market capitalization?
Catalyst Pharmaceuticals Inc market cap is approximately 3.85 billion.
What is Catalyst Pharmaceuticals Inc (CPRX) Earnings Per Share (EPS)?
The trailing EPS is $1.73, and the forward EPS is $3.18.
What is Catalyst Pharmaceuticals Inc (CPRX) Price-to-Earnings (P/E) ratio?
Catalyst Pharmaceuticals Inc current P/E ratio is 18.2, with a forward P/E of 9.9.
What is Catalyst Pharmaceuticals Inc (CPRX) EBITDA?
Catalyst Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 94.08 million.
Does Catalyst Pharmaceuticals Inc (CPRX) pay dividends?
No. Catalyst Pharmaceuticals Inc does not pay a dividend.
How did Catalyst Pharmaceuticals Inc (CPRX) perform in its most recent earnings report?
In the last report (March 31, 2026), Catalyst Pharmaceuticals Inc posted an EPS surprise of 23.44% and a revenue surprise of 0.82%.
When is Catalyst Pharmaceuticals Inc (CPRX) next earnings report?
Catalyst Pharmaceuticals Inc is expected to release its next earnings report on June 30, 2026.
What is Catalyst Pharmaceuticals Inc (CPRX) beta (volatility) score?
Catalyst Pharmaceuticals Inc has a beta of 0.742, indicating lower volatility than the overall market.
